First clinical proof of cccDNA elimination in hepatitis B positions PBGENE-HBV as the lead asset, contingent on whether Phase 2 sustains functional cure signals

Bull

Phase 2 initiates with a well-defined nucleoside analog discontinuation protocol, and patients who discontinue NAs after PBGENE-HBV dosing sustain HBsAg suppression and undetectable pgRNA without viral rebound, constituting functional cure signals. This would validate cccDNA elimination as a durable, clinically meaningful endpoint, sharply differentiate PBGENE-HBV from all current standard-of-care approaches, and de-risk the asset for a major partnership or pivotal program, driving substantial rerating of the stock.

Bear

The most likely failure modes are viral rebound upon NA discontinuation — indicating that residual, unedited cccDNA or integrated HBV DNA is sufficient to re-establish infection despite Phase 1 editing signals — or the emergence of significant hepatotoxicity at repeat-dosing schedules required for deeper cccDNA clearance. A failure to agree on a feasible NA withdrawal framework with global investigators, or insufficient editing depth at tolerable doses, could delay or prevent Part 2 initiation entirely, leaving the functional cure thesis unproven and the asset stranded in early-stage development.